BERKELEY HEIGHTS, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; 'Cyclacel' or the 'Company'), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will implement a 1-for-15 Reverse Stock Split of its common stock (“Reverse Stock Split”), effective at 5:00 p.m.

新泽西州伯克利高地，2023年12月12日（环球通讯社）--开发基于癌细胞生物学的创新药物的生物制药公司Cyclacel Pharmaceuticals，Inc.（纳斯达克股票代码：CYCC，纳斯达克股票代码：CYCCP；‘Cyclacel’或‘公司’），今天宣布将对其普通股实施15股1股的反向股票分割（“反向股票分割”），于下午5:00生效。

Eastern Time on Friday, December 15, 2023. The Reverse Stock Split, which was approved by stockholders at the Company’s Special Meeting of Stockholders on December 8, 2023, is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market.

东部时间2023年12月15日，星期五。2023年12月8日，公司股东在股东特别会议上批准了反向股票分割，主要目的是使公司符合维持其在纳斯达克资本市场上市的最低出价要求。

Beginning with the opening of trading on Monday, December 18, 2023, the Company’s common stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the existing symbol “CYCC” and a new CUSIP number 23254L801. At the effective time of the Reverse Stock Split, every fifteen (15) shares of the Company’s issued and outstanding common stock will be automatically converted into one (1) issued and outstanding share of common stock without any change in the par value of $0.001 per share.

自2023年12月18日（星期一）开盘以来，该公司的普通股将在纳斯达克资本市场上进行分割调整，现有符号为“CYCC”，新CUSIP编号为23254L801。在反向股票分割生效时，公司已发行和流通的普通股每十五（15）股将自动转换为一（1）股已发行和流通的普通股，每股面值不发生任何变化。

This will reduce the Company’s number of shares of outstanding common stock from approximately 12.6 million shares to approximately 0.84 million shares. The total authorized number of shares will not be reduced. Proportional adjustments will be made to the number of shares of common stock issuable upon exercise of the Company’s outstanding stock options, restricted stock units, and warrants, as well as the applicable exercise price.

这将使公司已发行普通股的股份数量从大约1260万股减少到大约84万股。授权股份总数不会减少。行使公司已发行的股票期权、限制性股票单位和认股权证后，将按比例调整可发行的普通股股数，以及适用的行使价格。

In addition, upon the effectiveness of the Reverse Stock Split, the conversion of the Company’s outstanding 6% convertible exchangeable preferred stock.

此外，在反向股票分割生效后，转换公司已发行的6%可转换可交换优先股。